US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SPYRE THERAPEUTICS INC

15.11

+0.45003.07%

Post-market: 15.110.00000.00%16:24 EDT

Volume:499.90K

Turnover:7.61M

Market Cap:910.76M

PE:-4.75

High:15.63

Open:14.95

Low:14.66

Close:14.66

Loading ...

Overview Company News Filings

Spyre Therapeutics Inc. Announces Inducement Awards Granting Stock Options to Non-Executive Employees Under 2018 Equity Plan

BUZZ-Leerink Partners begins coverage on Spyre Therapeutics with 'outperform'

Spyre Therapeutics Initiated at Outperform by Leerink Partners

Leerink Partners Initiates Spyre Therapeutics With Outperform Rating, $45 Price Target

MT Newswires Live

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics says first patient dosed in Phase 1 trial of SPY003

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody

Wolfe Research Initiates Spyre Therapeutics at Outperform With $27 Price Target

MT Newswires Live

Spyre Therapeutics Announces Grants of Inducement Awards

JonesTrading Sticks to Its Hold Rating for Spyre Therapeutics (SYRE)

Spyre Therapeutics Faces Compliance Hurdles After Transition from Smaller Reporting Company Status

BRIEF-Spyre Therapeutics Files For Mixed Shelf Offering Of Up To $500 Million- SEC Filing

Spyre Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Spyre Therapeutics Q4 2024 GAAP EPS $(0.81) Beats $(1.01) Estimate

Spyre Therapeutics Inc Files for Mixed Shelf Offering of up to $500 Mln- SEC Filing

THOMSON REUTERS

Spyre Therapeutics Inc expected to post a loss of 99 cents a share - Earnings Preview

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation

Spyre Therapeutics initiated with early-stage designation at Goldman Sachs

Spyre Therapeutics (SYRE) Gets a Buy from Stifel Nicolaus

Spyre Therapeutics Announces Grants of Inducement Awards

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SYRE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","market":"US","secType":"STK","nameCN":"SPYRE THERAPEUTICS INC","latestPrice":15.11,"timestamp":1746216000000,"preClose":14.66,"halted":0,"volume":499897,"hourTrading":{"tag":"盘后","latestPrice":15.11,"preClose":15.11,"latestTime":"16:24 EDT","volume":11744,"amount":177451.84,"timestamp":1746217480365},"delay":0,"floatShares":46620090,"shares":60275561,"eps":-3.180151,"marketStatus":"Post-Mkt","change":0.45,"latestTime":"05-02 16:30:25 EDT","open":14.95,"high":15.63,"low":14.66,"amount":7606820.121358,"amplitude":0.066166,"askPrice":15.2,"askSize":800,"bidPrice":9.15,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.180151,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1746230400000},"marketStatusCode":4,"adr":0,"listingDate":1460001600000,"exchange":"NASDAQ","adjPreClose":14.66,"preHourTrading":{"tag":"盘前","latestPrice":15.47,"preClose":14.66,"latestTime":"09:28 EDT","volume":855,"amount":12451.897665,"timestamp":1746192480030},"postHourTrading":{"tag":"盘后","latestPrice":15.11,"preClose":15.11,"latestTime":"16:24 EDT","volume":11744,"amount":177451.84,"timestamp":1746217480365},"volumeRatio":1.143487,"impliedVol":1.3561,"impliedVolPercentile":0.888},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","floatShares":46620090,"roa":"-27.43%","roe":"-59.28%","lyrEps":-3.180151,"volumeRatio":1.143487,"shares":60275561,"dividePrice":0,"high":15.63,"amplitude":0.066166,"preClose":14.66,"low":14.66,"week52Low":10.91,"pbRate":"2.52","week52High":40.49,"institutionHeld":0,"latestPrice":15.11,"committee":-0.777778,"eps":-3.180151,"divideRate":0,"volume":499897,"delay":0,"ttmEps":-3.180151,"open":14.95,"prevYearClose":23.28,"prevWeekClose":14.13,"prevMonthClose":15.23,"prevQuarterClose":16.135,"fiveDayClose":14.13,"twentyDayClose":13.99,"sixtyDayClose":23.56},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SYRE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532635871","title":"Spyre Therapeutics Inc. Announces Inducement Awards Granting Stock Options to Non-Executive Employees Under 2018 Equity Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2532635871","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532635871?lang=en_us&edition=fundamental","pubTime":"2025-05-03 04:05","pubTimestamp":1746216330,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., May 2, 2025 - Spyre Therapeutics, Inc. , a clinical-stage biotechnology company, has announced the approval of stock options as an equity inducement for seven non-executive employees. The company's independent Compensation Committee of the Board of Directors has granted options to purchase a total of 64,400 shares under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan. Approved on May 1, 2025, the stock options have a 10-year term with an exercise price of $14.66, matching the closing price of Spyre's common stock on that date. The vesting schedule stipulates that one-fourth of the shares become exercisable on the first anniversary of the employee's start date, with the remainder vesting monthly over four years, contingent on continuous service with the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nNDL10GsWv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2525489252","title":"BUZZ-Leerink Partners begins coverage on Spyre Therapeutics with 'outperform'","url":"https://stock-news.laohu8.com/highlight/detail?id=2525489252","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525489252?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:57","pubTimestamp":1744117076,"startTime":"0","endTime":"0","summary":"BUZZ-Leerink Partners begins coverage on Spyre Therapeutics with 'outperform'** Biotech firm Spyre Therapeutics' SYRE.O shares rise 3% to $12.76 premarket** Brokerage Leerink Partners initiates coverage with \"outperform\" rating** Sets PT at $45, representing more than triple upside to the stock's last close     ** Leerink Partners view SYRE as one of \"the most compelling prospective entrants in inflammatory bowel disease\" ** SYRE said in January it will begin mid-stage study of monotherapies, SPY001 , followed by SPY002 , SPY003 , to treat ulcerative colitis in mid-2025 and expects results in 2026** Brokerage says \"SYRE is well-capitalized to execute on its near-term plans, and the cadence of data catalysts out of the platform trial will pick up dramatically in 2026-2027\"** Company has cash, cash equivalents, and marketable securities balance of over $600 million as of December 31, 2024** Ten of 11 brokerages rate the stock \"buy\" or higher, one \"hold\"; their median PT is $55.75, accord","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nL3N3QM153:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"gpt_icon":0},{"id":"2525889960","title":"Spyre Therapeutics Initiated at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2525889960","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525889960?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:06","pubTimestamp":1744113960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SYRE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2025 08:06 ET (12:06 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","SYRE"],"gpt_icon":0},{"id":"2525985896","title":"Leerink Partners Initiates Spyre Therapeutics With Outperform Rating, $45 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2525985896","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525985896?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:52","pubTimestamp":1744113178,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) has an average rating of Buy and mean price target of $54.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","SYRE"],"gpt_icon":0},{"id":"2525730381","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2525730381","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525730381?lang=en_us&edition=fundamental","pubTime":"2025-04-05 04:05","pubTimestamp":1743797100,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., April 4, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 93,200 shares of common stock of Spyre to five non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended . The stock options were approved on April 1, 2025 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-200500867.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-200500867.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IBD","SYRE","LENZ","BK4139"],"gpt_icon":0},{"id":"2522319815","title":"Spyre Therapeutics says first patient dosed in Phase 1 trial of SPY003","url":"https://stock-news.laohu8.com/highlight/detail?id=2522319815","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522319815?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:10","pubTimestamp":1743106255,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) announced that it has initiated dosing in a healthy volunteer, Phase 1 clinical trial of its investigational half-life ex...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-says-first-patient-dosed-in-phase-1-trial-of-spy003?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-says-first-patient-dosed-in-phase-1-trial-of-spy003?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYRE","LENZ","BK4139"],"gpt_icon":0},{"id":"2522595385","title":"Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2522595385","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522595385?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"Preclinical data demonstrates that SPY003 is highly potent and has potential forquarterly or biannual dosing, suggesting opportunity for improved efficacy andconvenience over first-generation anti-IL-23 monoclonal antibodies. Interim pharmacokinetic and safety data from healthy volunteers for SPY003 anticipatedin the second half of 2025. SPY003 is an investigational, novel, extended half-life monoclonal antibody targeting IL-23, being developed for the potential treatment of IBD. IBD is a chronic condition characterized by inflammation in the gastrointestinal tract and encompasses two main disorders: ulcerative colitis and Crohn's disease. In the United States, it is estimated that approximately 2.4 million individuals currently have IBD. In head-to-head preclinical studies, SPY003 demonstrated equivalent potency to risankizumab in inhibiting pSTAT signaling and IL-17 production and exhibited significantly longer half-life in non-human primates with the potential to deliver dosing in h","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-first-participant-200500981.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-first-participant-200500981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IBD","SYRE","BK4181","BK4218","PK","LENZ","BK4139"],"gpt_icon":0},{"id":"2520626310","title":"Wolfe Research Initiates Spyre Therapeutics at Outperform With $27 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2520626310","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520626310?lang=en_us&edition=fundamental","pubTime":"2025-03-18 19:16","pubTimestamp":1742296588,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) has an average rating of buy and mean price target of $55.11, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","SYRE"],"gpt_icon":0},{"id":"2517466136","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2517466136","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517466136?lang=en_us&edition=fundamental","pubTime":"2025-03-08 05:40","pubTimestamp":1741383600,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., March 7, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 132,200 shares of common stock of Spyre to five non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended . The stock options were approved on March 3, 2025 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-214000337.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-214000337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SYRE","IBD","LENZ","BK4139"],"gpt_icon":0},{"id":"2516800166","title":"JonesTrading Sticks to Its Hold Rating for Spyre Therapeutics (SYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2516800166","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516800166?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:29","pubTimestamp":1741004970,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Debanjana Chatterjee reiterated a Hold rating on Spyre Therapeutics (SYRE – Research Report) today. The company’s shares close...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-its-hold-rating-for-spyre-therapeutics-syre?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-its-hold-rating-for-spyre-therapeutics-syre?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYRE"],"gpt_icon":0},{"id":"2516535729","title":"Spyre Therapeutics Faces Compliance Hurdles After Transition from Smaller Reporting Company Status","url":"https://stock-news.laohu8.com/highlight/detail?id=2516535729","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516535729?lang=en_us&edition=fundamental","pubTime":"2025-03-01 14:01","pubTimestamp":1740808897,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics, Inc (SYRE) has disclosed a new risk, in the Share Price & Shareholder Rights category. Spyre Therapeutics, Inc. faces significa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/spyre-therapeutics-faces-compliance-hurdles-after-transition-from-smaller-reporting-company-status?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/spyre-therapeutics-faces-compliance-hurdles-after-transition-from-smaller-reporting-company-status?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYRE","LENZ","BK4139"],"gpt_icon":0},{"id":"2514770356","title":"BRIEF-Spyre Therapeutics Files For Mixed Shelf Offering Of Up To $500 Million- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2514770356","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514770356?lang=en_us&edition=fundamental","pubTime":"2025-02-28 06:23","pubTimestamp":1740695001,"startTime":"0","endTime":"0","summary":"BRIEF-Spyre Therapeutics Files For Mixed Shelf Offering Of Up To $500 Million- SEC FilingFeb 27  - Spyre Therapeutics Inc SYRE.O:SPYRE THERAPEUTICS INC FILES FOR MIXED SHELF OFFERING OF UP TO $500 MILLION- SEC FILINGSource text: [ID:n0001628280-25-008686]Further company coverage: SYRE.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI15K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2514353725","title":"Spyre Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2514353725","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514353725?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:43","pubTimestamp":1740692590,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummarySpyre Therapeutics Inc SYRE.OQ reported a quarterly adjusted loss of 81 cents per share for the quarter ended","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL5N3PI38Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"gpt_icon":0},{"id":"2514353050","title":"Spyre Therapeutics Q4 2024 GAAP EPS $(0.81) Beats $(1.01) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2514353050","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514353050?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:41","pubTimestamp":1740692469,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Q4 2024 GAAP EPS $(0.81) Beats $(1.01) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/02/44026855/spyre-therapeutics-q4-2024-gaap-eps-0-81-beats-1-01-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","SYRE"],"gpt_icon":0},{"id":"2514935824","title":"Spyre Therapeutics Inc Files for Mixed Shelf Offering of up to $500 Mln- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2514935824","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514935824?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:25","pubTimestamp":1740691554,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI15K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2514605528","title":"Spyre Therapeutics Inc  expected to post a loss of 99 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2514605528","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514605528?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:07","pubTimestamp":1740604027,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc  expected to post a loss of99cents a share - Earnings Preview Spyre Therapeutics Inc SYRE.OQ SYRE.O is expected to show a rise in quarterly revenue when it reports  results on F","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nL5N3PH2S1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE"],"gpt_icon":0},{"id":"2512877102","title":"Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation","url":"https://stock-news.laohu8.com/highlight/detail?id=2512877102","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512877102?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:00","pubTimestamp":1739970000,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Feb. 19, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease  and other immune-mediated diseases, today announced a poster presentation at the 20th Congress of the European Crohn's and Colitis Organisation , held February 19-22, 2025, in Berlin, Germany, showing that combined inhibition of α4β7 integrin and TL1A cytokine is superior to either monotherapy in mouse models of colitis and coadministration demonstrates no drug-drug effects on exposure in non-human primates .Forward-Looking StatementsCertain statements in this press release, other than purely historical information, may constitute \"forward-looking statements\" within the meaning of the federal securities laws, including for purpos","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-poster-presentation-130000431.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-poster-presentation-130000431.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SYRE","LENZ","IBD"],"gpt_icon":0},{"id":"2512318132","title":"Spyre Therapeutics initiated with early-stage designation at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2512318132","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512318132?lang=en_us&edition=fundamental","pubTime":"2025-02-18 17:40","pubTimestamp":1739871605,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst Paul Choi initiated Spyre Therapeutics (SYRE) with an early-stage biotech designation. The firm sees an “attractive mix of cl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-initiated-with-early-stage-designation-at-goldman-sachs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-initiated-with-early-stage-designation-at-goldman-sachs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z3B42.SGD","BK4550","IE0004091025.USD","LU1868837300.USD","LU2237438978.USD","LU2237443978.SGD","LU1791807156.HKD","IE00B19Z3581.USD","LU1868836757.USD","LU2750360997.AUD","LU2237443382.USD","LU2237443549.SGD","LU1668664300.SGD","LU2471134952.CNY","IE0034235188.USD","LU2471134523.USD","LU2471134796.USD","BK4585","BK4552","IE00BSNM7G36.USD","LU0061475181.USD","BK4533","LENZ","IE00BFXG1179.USD","LU2237443622.USD","LU2750360641.GBP","IE0002270589.USD","BK4139","LU2237443465.HKD","BK4588","LU1868836591.USD","BK4516","LU1868837136.USD","LU0096364046.USD","BK4127","LU1868836914.USD","BK4504","LU2237443895.HKD","IE0004086264.USD","SYRE","LU0106831901.USD","LU2471134879.HKD"],"gpt_icon":0},{"id":"2510851902","title":"Spyre Therapeutics (SYRE) Gets a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2510851902","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510851902?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:45","pubTimestamp":1739191554,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Spyre Therapeutics (SYRE – Research Report) today and set a price target of $7...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/spyre-therapeutics-syre-gets-a-buy-from-stifel-nicolaus-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/spyre-therapeutics-syre-gets-a-buy-from-stifel-nicolaus-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CFA","SF","BK4127","SYRE"],"gpt_icon":0},{"id":"2509777836","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2509777836","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509777836?lang=en_us&edition=fundamental","pubTime":"2025-02-08 06:13","pubTimestamp":1738966380,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Feb. 7, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 35,000 shares of common stock of Spyre to three non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended . The stock options were approved on February 3, 2025 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635.Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease  and other immune-mediated disease products by combining bes","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-221300168.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-221300168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IBD","SYRE","LENZ"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":58,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-27","symbol":"SYRE","fiscalQuarterEnding":"2024/12","expectedEps":-1.1,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":-0.81},{"market":"US","date":"2024-11-07","symbol":"SYRE","fiscalQuarterEnding":"2024/09","expectedEps":-0.8,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-1.36},{"market":"US","date":"2024-08-07","symbol":"SYRE","fiscalQuarterEnding":"2024/06","expectedEps":-0.9,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"post","actualEps":-0.86},{"market":"US","date":"2024-05-09","symbol":"SYRE","fiscalQuarterEnding":"2024/03","expectedEps":-0.9,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"post","actualEps":-1.2},{"market":"US","date":"2024-02-29","symbol":"SYRE","fiscalQuarterEnding":"2023/12","expectedEps":-0.48,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1709182800000,"reportTimeType":"post","actualEps":-2.28}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.25,"hold":0.0833,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":12,"updateTime":1744171200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SYRE","date":"2025-05-01","current":-4.413064,"percent":0.528358,"low":-10.261647,"twenty":-7.371109,"median":-4.789976,"eighty":-3.456852,"high":-0.199399,"avg":-5.185138,"sd":2.040117,"marketCap":917996794},"quantilePoints":[{"date":"2023-12-01","current":-1.902619,"twenty":-1.228042,"median":-0.216176,"eighty":-0.20611,"marketCap":560191990},{"date":"2023-12-08","current":-2.024974,"twenty":-2.048834,"median":-1.98164,"eighty":-0.890753,"marketCap":596217199},{"date":"2023-12-15","current":-1.815535,"twenty":-2.023412,"median":-1.966856,"eighty":-1.735642,"marketCap":534551743},{"date":"2023-12-22","current":-2.106706,"twenty":-2.023412,"median":-1.950531,"eighty":-1.82549,"marketCap":620281740},{"date":"2023-12-29","current":-2.507984,"twenty":-2.09023,"median":-1.996425,"eighty":-1.840422,"marketCap":738430643},{"date":"2024-01-05","current":-2.757559,"twenty":-2.278228,"median":-2.002935,"eighty":-1.873937,"marketCap":811913497},{"date":"2024-01-12","current":-2.567931,"twenty":-2.588728,"median":-2.024974,"eighty":-1.89995,"marketCap":756080936},{"date":"2024-01-19","current":-2.66458,"twenty":-2.653814,"median":-2.09023,"eighty":-1.902486,"marketCap":784537532},{"date":"2024-01-26","current":-3.303198,"twenty":-2.742878,"median":-2.292052,"eighty":-1.915254,"marketCap":972567189},{"date":"2024-02-02","current":-3.16373,"twenty":-3.116751,"median":-2.567931,"eighty":-1.947266,"marketCap":931503241},{"date":"2024-02-09","current":-2.89825,"twenty":-3.138772,"median":-2.61809,"eighty":-1.978684,"marketCap":853337655},{"date":"2024-02-16","current":-2.760005,"twenty":-3.112591,"median":-2.66458,"eighty":-1.997649,"marketCap":812633917},{"date":"2024-02-23","current":-2.496973,"twenty":-3.08641,"median":-2.66458,"eighty":-2.000865,"marketCap":735188752},{"date":"2024-03-01","current":-3.357028,"twenty":-3.117974,"median":-2.696389,"eighty":-2.009323,"marketCap":988416432},{"date":"2024-03-08","current":-4.14553,"twenty":-3.186241,"median":-2.748383,"eighty":-2.021849,"marketCap":1404464057},{"date":"2024-03-15","current":-4.473117,"twenty":-3.315921,"median":-2.757559,"eighty":-2.032927,"marketCap":1515447446},{"date":"2024-03-22","current":-4.253303,"twenty":-3.374155,"median":-2.84075,"eighty":-2.069838,"marketCap":1440976508},{"date":"2024-03-28","current":-3.948124,"twenty":-3.948124,"median":-2.884793,"eighty":-2.09023,"marketCap":1337584817},{"date":"2024-04-05","current":-3.822655,"twenty":-3.997689,"median":-2.933117,"eighty":-2.106706,"marketCap":1295077328},{"date":"2024-04-12","current":-4.169482,"twenty":-4.017483,"median":-2.950857,"eighty":-2.22293,"marketCap":1412578691},{"date":"2024-04-19","current":-3.844264,"twenty":-4.019298,"median":-3.071974,"eighty":-2.361175,"marketCap":1302398285},{"date":"2024-04-26","current":-3.508242,"twenty":-4.017483,"median":-3.149049,"eighty":-2.496973,"marketCap":1188557401},{"date":"2024-05-03","current":-4.312212,"twenty":-4.026871,"median":-3.180093,"eighty":-2.505537,"marketCap":1460934345},{"date":"2024-05-10","current":-4.183809,"twenty":-4.050631,"median":-3.290964,"eighty":-2.507984,"marketCap":1417432578},{"date":"2024-05-17","current":-4.180278,"twenty":-4.096445,"median":-3.334395,"eighty":-2.567931,"marketCap":1522561849},{"date":"2024-05-24","current":-3.614061,"twenty":-4.096445,"median":-3.364368,"eighty":-2.569154,"marketCap":1316331249},{"date":"2024-05-31","current":-3.765942,"twenty":-4.092735,"median":-3.38639,"eighty":-2.608303,"marketCap":1371650246},{"date":"2024-06-07","current":-4.825529,"twenty":-4.146052,"median":-3.527045,"eighty":-2.61809,"marketCap":1757578310},{"date":"2024-06-14","current":-4.511821,"twenty":-4.180278,"median":-3.580903,"eighty":-2.629835,"marketCap":1643317946},{"date":"2024-06-21","current":-3.573485,"twenty":-4.180278,"median":-3.584639,"eighty":-2.648431,"marketCap":1301552501},{"date":"2024-06-28","current":-3.166361,"twenty":-4.18028,"median":-3.584639,"eighty":-2.659197,"marketCap":1153267940},{"date":"2024-07-05","current":-3.59161,"twenty":-4.180278,"median":-3.582547,"eighty":-2.666048,"marketCap":1308154211},{"date":"2024-07-12","current":-3.922049,"twenty":-4.1738,"median":-3.59161,"eighty":-2.678038,"marketCap":1428508461},{"date":"2024-07-15","current":-4.13816,"twenty":-4.171641,"median":-3.593701,"eighty":-2.681708,"marketCap":1507221157},{"date":"2024-08-02","current":-3.753344,"twenty":-4.169482,"median":-3.595793,"eighty":-2.685378,"marketCap":1367061777},{"date":"2024-08-09","current":-6.895906,"twenty":-4.180278,"median":-3.619566,"eighty":-2.707399,"marketCap":1282507443},{"date":"2024-08-16","current":-7.250942,"twenty":-4.233229,"median":-3.6476,"eighty":-2.720856,"marketCap":1348537529},{"date":"2024-08-23","current":-6.762084,"twenty":-4.253955,"median":-3.674487,"eighty":-2.748383,"marketCap":1257619180},{"date":"2024-08-30","current":-7.666062,"twenty":-4.345056,"median":-3.707046,"eighty":-2.757559,"marketCap":1425741938},{"date":"2024-09-06","current":-7.657869,"twenty":-4.411655,"median":-3.73151,"eighty":-2.757559,"marketCap":1424218166},{"date":"2024-09-13","current":-7.786586,"twenty":-4.705472,"median":-3.759643,"eighty":-2.757559,"marketCap":1448156979},{"date":"2024-09-20","current":-8.323214,"twenty":-4.847589,"median":-3.822655,"eighty":-2.759516,"marketCap":1547959640},{"date":"2024-09-27","current":-7.956335,"twenty":-5.135333,"median":-3.898142,"eighty":-2.824601,"marketCap":1479727208},{"date":"2024-10-04","current":-7.76742,"twenty":-6.713509,"median":-3.922049,"eighty":-2.854452,"marketCap":1444592598},{"date":"2024-10-11","current":-7.452562,"twenty":-6.898091,"median":-3.929227,"eighty":-2.87941,"marketCap":1386034914},{"date":"2024-10-18","current":-8.969358,"twenty":-7.252035,"median":-3.990015,"eighty":-2.895559,"marketCap":1668130191},{"date":"2024-10-25","current":-9.226721,"twenty":-7.3874,"median":-4.004712,"eighty":-2.923697,"marketCap":1715994732},{"date":"2024-10-31","current":-9.352664,"twenty":-7.525937,"median":-4.015348,"eighty":-2.933729,"marketCap":1739417806},{"date":"2024-11-08","current":-8.930417,"twenty":-7.599425,"median":-4.026871,"eighty":-2.936176,"marketCap":1919164435},{"date":"2024-11-15","current":-7.483663,"twenty":-7.650222,"median":-4.048996,"eighty":-2.944985,"marketCap":1608254249},{"date":"2024-11-22","current":-7.375771,"twenty":-7.638736,"median":-4.07743,"eighty":-3.008113,"marketCap":1585067940},{"date":"2024-11-29","current":-7.766414,"twenty":-7.641472,"median":-4.091807,"eighty":-3.046772,"marketCap":1669017834},{"date":"2024-12-06","current":-6.979665,"twenty":-7.646653,"median":-4.11994,"eighty":-3.06708,"marketCap":1499943921},{"date":"2024-12-13","current":-6.534387,"twenty":-7.641035,"median":-4.14553,"eighty":-3.107208,"marketCap":1404252782},{"date":"2024-12-20","current":-6.318577,"twenty":-7.622349,"median":-4.17488,"eighty":-3.133634,"marketCap":1357874868},{"date":"2024-12-27","current":-6.575363,"twenty":-7.605285,"median":-4.180282,"eighty":-3.151985,"marketCap":1413058715},{"date":"2025-01-03","current":-6.515264,"twenty":-7.602508,"median":-4.208519,"eighty":-3.16373,"marketCap":1400143347},{"date":"2025-01-10","current":-6.561704,"twenty":-7.598137,"median":-4.247699,"eighty":-3.165835,"marketCap":1410123404},{"date":"2025-01-17","current":-5.613781,"twenty":-7.595453,"median":-4.253955,"eighty":-3.16915,"marketCap":1206412821},{"date":"2025-01-24","current":-5.957984,"twenty":-7.590053,"median":-4.295985,"eighty":-3.182143,"marketCap":1280382658},{"date":"2025-01-31","current":-6.083645,"twenty":-7.581791,"median":-4.354133,"eighty":-3.191991,"marketCap":1307387519},{"date":"2025-02-07","current":-6.517996,"twenty":-7.571599,"median":-4.396289,"eighty":-3.243978,"marketCap":1400730409},{"date":"2025-02-14","current":-6.195648,"twenty":-7.5588,"median":-4.51381,"eighty":-3.285739,"marketCap":1331457069},{"date":"2025-02-21","current":-6.12189,"twenty":-7.543691,"median":-4.721977,"eighty":-3.295858,"marketCap":1315606390},{"date":"2025-02-28","current":-5.184327,"twenty":-7.527033,"median":-4.825529,"eighty":-3.30956,"marketCap":1078433261},{"date":"2025-03-07","current":-5.940106,"twenty":-7.521557,"median":-4.885482,"eighty":-3.331336,"marketCap":1235649000},{"date":"2025-03-14","current":-5.224396,"twenty":-7.515906,"median":-5.129477,"eighty":-3.352623,"marketCap":1086768364},{"date":"2025-03-21","current":-5.259167,"twenty":-7.500881,"median":-5.171542,"eighty":-3.359964,"marketCap":1094001432},{"date":"2025-03-28","current":-5.125877,"twenty":-7.471223,"median":-5.184327,"eighty":-3.369262,"marketCap":1066274674},{"date":"2025-04-04","current":-4.052513,"twenty":-7.451349,"median":-5.158757,"eighty":-3.380517,"marketCap":842995751},{"date":"2025-04-11","current":-3.456852,"twenty":-7.428767,"median":-5.125877,"eighty":-3.399507,"marketCap":719087442},{"date":"2025-04-17","current":-3.598835,"twenty":-7.393254,"median":-4.931737,"eighty":-3.419927,"marketCap":748622467},{"date":"2025-04-25","current":-4.326136,"twenty":-7.374839,"median":-4.857093,"eighty":-3.429694,"marketCap":899914125},{"date":"2025-05-01","current":-4.413064,"twenty":-7.371109,"median":-4.789976,"eighty":-3.456852,"marketCap":917996794}],"updateTime":1746203454287}}}